# US 2006/0040861 A1 · Method of treating, preventing, and diagnosing prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040861 A1
- Document ID: US20060040861A1
- Status: Published application
- Kind: A1
- Application number: 11/191,433
- Filed: 2005-07-28
- Published: 2006-02-23
- Earliest claimed: 2004-07-29
- Inventors: Yoshiki Iwamoto
- Web page: https://patentgrep.com/patent/US20060040861A1

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating prostate cancer in a prostate cancer patient is disclosed. In one embodiment of the present invention, the method comprises the step of decreasing or blocking the patient's leptin interaction with leptin receptor or increasing adiponectin interaction with adiponectin receptors.

## Claims

### Claim 1

A method of treating prostate cancer in a prostate cancer patient, comprising the step of decreasing or blocking the patient's leptin function or increasing adiponectin function

### Claim 2 (depends on 1)

The method of claim 1 additionally comprising the step of decreasing or blocking the patient's IGF or IL-6 function.

### Claim 3 (depends on 1)

The method of claim 1 wherein siRNA is used to decrease leptin interaction.

### Claim 4 (depends on 3)

The method of claim 3 wherein the siRNA molecule is selected from the group of SEQ ID NO:1 and SEQ ID NO:2.

### Claim 5 (depends on 1)

The method of claim 1 wherein antibodies are used to decrease leptin interaction.

### Claim 6 (depends on 1)

The method of claim 1 wherein analogous leptin peptides are used to decrease leptin and/or adiponectin function.

### Claim 7 (depends on 6)

The method of claim 6 wherein the peptides are selected from the group consisting of SEQ ID NOs:3-8.

### Claim 8 (depends on 1)

The method of claim 1 wherein control of leptin function is through modification of the patient's body fat.

### Claim 9 (depends on 1)

The method of claim 1 wherein the increase in adiponectin function is accomplished by administration of native or recombinant adiponectin or a nucleic acid sequence encoding adiponectin.

### Claim 10 (depends on 1)

The method of claim 1 wherein increase in adiponectin function is via antibodies or small molecules that stimulate adiponectin receptors.

### Claim 11 (depends on 1)

The method of claim 1 wherein native or recombinant adiponectin or a nucleic acid sequence encoding adiponectin is administered systemically.

### Claim 12 (depends on 1)

The method of claim 1 wherein native or recombinant adiponectin or a nucleic acid sequence encoding adiponectin is administered directly to tumors or tissue surrounding a tumor.

### Claim 13

A method of diagnosing a patient's prostate cancer risk comprising the step of examining the patient's blood concentration profiles of at least one adipose cytokines and correlating the level with prostate cancer diagnosis.

### Claim 14 (depends on 13)

The method of claim 13 wherein the adipose cytokine is selected from the group consisting of leptin, adiponectin IGF-I, IGF-II, IL-6, TNF-α. PSA and DHT.

### Claim 15 (depends on 14)

The method of claim 14 wherein multiple cytokines are examined.

### Claim 16 (depends on 15)

The method of claim 15 wherein one of the selected cytokines is leptin.

### Claim 17 (depends on 15)

The method of claim 15 wherein one of the selected cytokines is adiponectin.
